Form 4: Nautilus Biotechnology CFO Anna Mowry Granted Stock Options
SEC Form 4 Filing
Anna Mowry, CFO and Treasurer of Nautilus Biotechnology, was granted stock options for 160,000 shares on March 3, 2025, according to a Form 4 filing.
Summary
- A Form 4 filing reveals that Anna Mowry, CFO and Treasurer of Nautilus Biotechnology, received stock options.
- On March 3, 2025, Mowry was granted options to purchase 160,000 shares of Nautilus Biotechnology's common stock at an exercise price of $1.24 per share.
- The options vest over a period of 48 months, with 25% vesting on the first anniversary of the Vesting Commencement Date (January 1, 2025) and the remainder vesting monthly thereafter.
- Mowry also has a power of attorney designating individuals to act on her behalf in matters related to securities filings.
Sentiment
Score: 6
Explanation: The document itself is neutral, simply reporting a stock option grant. The sentiment is slightly positive as it indicates the company is incentivizing its executives.
Positives
- The granting of stock options to a key executive like the CFO can be seen as an incentive to align their interests with those of the shareholders.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common practice in the biotechnology industry to attract and retain key talent. These grants align the interests of executives with those of shareholders by incentivizing them to increase the company's value.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
- The size of the grant (160,000 shares) would need to be compared to grants made to executives at comparable companies of similar market capitalization to determine if it is within industry norms.
- Companies like Pacific Biosciences, Twist Bioscience, and Singular Genomics are comparible companies.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning management's interests with theirs.
- Employees may see this as a positive sign of investment in leadership.
Key Dates
| Date | Description |
|---|---|
| February 21, 2025 | Date of execution of Power of Attorney. |
| January 1, 2025 | Vesting Commencement Date for the stock options. |
| March 3, 2025 | Date of the stock option grant. |
| March 4, 2025 | Date of signature for the Form 4 filing. |
| January 1, 2026 | First vesting date (25% of shares) for the stock options. |
| March 3, 2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.